Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 57Active not recruiting 29Recruiting 17Terminated 10Withdrawn 4Not yet recruiting 1No longer available 1Approved for marketing 1

Sponsor Class

OTHER 8INDUSTRY 4NIH 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Breast Neoplasms 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × olaparib × Clear all
NCT06829199 2026-02-19

MK-5890-003

Merck Sharp & Dohme LLC

Phase 2 Withdrawn
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05411679 2023-06-12

EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

Ellipses Pharma

Phase 2 Withdrawn
GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04239014 2021-03-10

DUETTE

AstraZeneca

Phase 2 Withdrawn
Gynecologic

Ovarian Neoplasms

NCT02392676 2016-05-02

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

AstraZeneca

Phase 3 Withdrawn
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡